Takahara Takeshi

Prof. Takahara Takeshi

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2023 in Cancers
Verified
Journal Article
Open access
PDF file
YKYutaro Kato
Yutaro Kato
Atsushi SugiokaAtsushi Sugioka
Atsushi Sugioka
MKMasayuki Kojima
Masayuki Kojima
SMSatoshi Mii
Satoshi Mii
YUYuichiro Uchida
Yuichiro Uchida
IUIchiro Uyama
Ichiro Uyama
Surgical techniques and outcomes of minimally invasive anatomic liver resection (AR) using the extrahepatic Glissonian approach for hepatocellular carcinoma (HCC) are undefined. In 327 HCC cases undergoing 185 open (OAR) and 142 minimally invasive (MIAR; 102 laparoscopic and 40 robotic) ARs, perioperative and long-term outcomes were compared between the approaches, using propensity score matching. After matching (91:91), compared to OAR, MIAR was significantly associated with longer operative time (643 vs. 579 min, p = 0.028); less blood loss (274 vs. 955 g, p < 0.0001); a lower transfusion rate (17.6% vs. 47.3%, p < 0.0001); lower rates of major 90-day morbidity (4.4% vs. 20.9%, p = 0.0008), bile leak or collection (1.1% vs. 11.0%, p = 0.005), and 90-day mortality (0% vs. 4.4%, p = 0.043); and shorter hospital stay (15 vs. 29 days, p < 0.0001). On the other hand, laparoscopic and robotic AR cohorts after matching (31:31) had comparable perioperative outcomes. Overall and recurrence-free survivals after AR for newly developed HCC were comparable between OAR and MIAR, with potentially improved survivals in MIAR. The survivals were comparable between laparoscopic and robotic AR. MIAR was technically standardized using the extrahepatic Glissonian approach. MIAR was safe, feasible, and oncologically acceptable and would be the first choice of AR in selected HCC patients.

28 May 2023 in Cancers
Verified
Journal Article
Open access
PDF file
TKTeiji Kuzuya
Teiji Kuzuya
NKNaoto Kawabe
Naoto Kawabe
MAMizuki Ariga
Mizuki Ariga
EOEizaburo Ohno
Eizaburo Ohno
KFKohei Funasaka
Kohei Funasaka
YHYoshiki Hirooka
Yoshiki Hirooka
(1) Background: This study aimed to investigate clinical outcomes for cabozantinib in clinical practice in patients with advanced hepatocellular carcinoma (HCC) previously treated with atezolizumab plus bevacizumab (Atz/Bev), with a focus on whether patients met criteria of Child–Pugh Class A and Eastern Cooperative Oncology Group performance status (ECOG-PS) score 0/1 at baseline. (2) Methods: Eleven patients (57.9%) met the criteria of both Child–Pugh class A and ECOG-PS score 0/1 (CP-A+PS-0/1 group) and eight patients (42.1%) did not (Non-CP-A+PS-0/1 group); efficacy and safety were retrospectively evaluated. (3) Results: Disease control rate was significantly higher in the CP-A+PS-0/1 group (81.1%) than in the non-CP-A+PS-0/1 group (12.5%). Median progression-free survival, overall survival and duration of cabozantinib treatment were significantly longer in the CP-A+PS-0/1 group (3.9 months, 13.4 months, and 8.3 months, respectively) than in the Non-CP-A+PS-0/1 group (1.2 months, 1.7 months, and 0.8 months, respectively). Median daily dose of cabozantinib was significantly higher in the CP-A+PS-0/1 group (22.9 mg/day) than in the non-CP-A+PS-0/1 group (16.9 mg/day). (4) Conclusions: Cabozantinib in patients previously treated with Atz/Bev has potential therapeutic efficacy and safety if patients have good liver function (Child–Pugh A) and are in good general condition (ECOG-PS 0/1).


6 December 2021 in Langenbeck's Archives of Surgery
Verified
Journal Article
Open access
PDF file
HKHirokatsu Katagiri
Hirokatsu Katagiri
HNHiroyuki Nitta
Hiroyuki Nitta
TTTakahara Takeshi
Takahara Takeshi
YHYasushi Hasegawa
Yasushi Hasegawa
SKSyoji Kanno
Syoji Kanno
ASAkira Sasaki
Akira Sasaki
Purpose: Laparoscopic left lateral sectionectomy (LLLS) is a feasible and safe procedure with a relatively smooth learning curve. However, single-incision LLLS requires extensive surgical experience and advanced techniques. The aim of this study is to report the standardized single-incision plus one-port LLLS (reduced port LLLS, RPLLLS) technique and evaluate its safety, feasibility, and effectiveness for junior surgeons. Methods: Between January 2008 and November 2020, the clinical records of 49 patients who underwent LLLS, divided into the conventional LLLS (n = 37) and the RPLLLS group (n = 12), were retrospectively reviewed. The patient characteristics, pathologic results, and operative outcomes were evaluated. Results: A history of previous abdominal surgery in the RPLLLS group was significantly high (56.8% vs. 91.7%, p = 0.552). Notably, junior surgeons performed 62.2% of the conventional LLLSs and 58.4% of the standardized RPLLLSs. There were no significant differences between the two groups in terms of median operative time (121.0 vs. 113.5, p = 0.387), median blood loss (13.0 vs. 8.5, p = 0.518), median length of hospital stays (7.0 vs. 7.0, p = 0.408), and morbidity rate (2.7% vs. 0%, p = 0.565), respectively. Conclusion: This standardized RPLLLS is a feasible and safe alternative to conventional LLLS and may become the ideal training procedure for both junior surgeons and surgeons aiming to learn more complex procedures.

10 February 2025 in Surgical Oncology
Verified
Journal Article
Closed access
YUYuichiro Uchida
Yuichiro Uchida
TTTakahara Takeshi
Takahara Takeshi
TKTakahisa Kawase
Takahisa Kawase
TMTakuya Mizumoto
Takuya Mizumoto
MNMasaya Nakauchi
Masaya Nakauchi
KSKoichi Suda
Koichi Suda

2 January 2024 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
TMTakuya Mizumoto
Takuya Mizumoto
TTTakahara Takeshi
Takahara Takeshi
ANAkihiro Nishimura
Akihiro Nishimura
SMSatoshi Mii
Satoshi Mii
YUYuichiro Uchida
Yuichiro Uchida
KSKoichi Suda
Koichi Suda